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Abstract
 Introduction Published data on hypertension incidence and management in Anderson–Fabry disease are scant and the 
contribution of elevated blood pressure to organ damage is not well recognized.
Aim Therefore, we have assessed blood pressure values and their possible correlations with clinical findings in a well 
described cohort of Fabry patients.
Methods Between January 2015 and May 2019, all adult Fabry patients (n = 24 females, n = 8 males) referred to our insti-
tute were prospectively enrolled. During the first examination patient’s genotype and clinical characteristics were recorded. 
Blood pressure data were obtained by standard observed office measurements followed, within 6 months, by ambulatory 
blood pressure monitoring and home self-recordings. Organ involvement, including kidneys, heart and brain, was monitored 
over time. Consequently, patients were defined as clinically stable or progressive through the Fabry Stabilization Index.
Results The standard office measurements have diagnosed hypertension in three (9.37%) patients, but the ambulatory 
monitoring showed elevated blood pressure in six (18.75%) patients, revealing three cases of masked hypertension. All the 
hypertensive patients were females and, compared with normotensive subjects, they presented a lower glomerular filtration 
rate (p < 0.05) and a more advanced cardiac hypertrophy (p < 0.05). Four (66.7%) of them were diagnosed with a progres-
sive form of the disease through the Fabry Stabilization Index while the majority of the normotensive group (84.6%, n = 19) 
was stable over time. No correlation was found between the prevalence of hypertension and the type of mutations causing 
Fabry disease.
Conclusion Hypertension can be found in a restricted portion of clinically stable Fabry patients. In contrast, patients pre-
senting with a progressive organ involvement, particularly renal impairment, have a major risk of developing uncontrolled 
blood pressure, and should be followed carefully. Moreover, the ambulatory blood pressure monitoring proved to be useful 
to reveal masked hypertension, which can contribute to the progressive worsening of the organ damage. Therefore, a proper 
diagnosis and therapy of hypertension may improve the outcome of Fabry patients.
Keywords Anderson–Fabry disease · Lysosomal storage disorder · Hypertension · Masked hypertension · Blood pressure 
monitoring
1 Introduction
Anderson–Fabry disease (AFD) is a rare X-linked sphin-
golipid storage disorder caused by a mutation in the GLA 
gene leading to a deficient activity of the lysosomal enzyme 
α-galactosidase A (α-Gal A). The reduced or absent activ-
ity of the enzyme results in a progressive lysosomal accu-
mulation of globotriaosylceramide (Gb3) and its derivates, 
including globotriaosylsphingosine (lyso-Gb3), within dif-
ferent body cells [1].
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The phenotypic spectrum of the disease comprises a “clas-
sic” form characterized by a total, or almost total, absence of 
α-Gal A activity and an early onset of the symptoms, gener-
ally during childhood or adolescence, with neuropathic pain, 
skin lesions (angiokeratomas), gastrointestinal symptoms and 
corneal opacities (cornea verticillata) [2]. Advancing with age, 
the progressive glycosphingolipid accumulation, particularly 
in vascular endothelial cells, cardiomyocytes and renal podo-
cytes, leads to cerebrovascular disease, cardiomyopathy and 
renal failure [3] resulting in severe morbidity and premature 
death [4].
In contrast, two other categories of the disease are increas-
ingly diagnosed: the “late-onset” and the “genetic variant of 
unknown significance” (GVUS) [5]. The former generally 
leads to a milder disease in adulthood, especially in females, 
and often involves a single organ system (usually cardiac or 
renal), while the latter is associated with unclear and variable 
pathological consequences or no clinical disease at all [6].
Data on blood pressure (BP) monitoring in AFD patients 
are scant, however, those available have revealed a significant 
prevalence of hypertension, especially in cases with moder-
ate to severe kidney impairment [7–11] and it becomes more 
prevalent with the progression of the renal disease [8].
Kleinert et al. examined uncontrolled hypertension, defined 
as systolic BP (SBP) ≥ 130 mmHg and/or diastolic BP (DBP) 
≥ 80 mmHg, among 391 patients with AFD participating in 
the Fabry Outcome Survey (FOS). Uncontrolled hyperten-
sion was diagnosed in 52.4% of the participants (57% males 
and 47% females) progressively increasing with the decline 
of glomerular filtration rate (GFR) estimated using the short 
Modification of Diet in Renal Disease (MDRD) formula [7].
On the contrary, analysing 105 male AFD patients, Bran-
ton et al. showed that hypertension (SBP ≥ 140 mmHg and/
or DBP ≥ 90 mmHg) was diagnosed in only one-third of the 
patients (30%) and, in most cases, was not present until the 
onset, or long after the onset, of renal impairment or end-
stage renal disease (ESRD) [12].
Given the wide and complex spectrum of AFD and the 
potential negative impact of hypertension on target organ 
damage (kidney, heart and nervous system), an appropriate 
algorithm for the diagnosis and therapy of elevated blood 
pressure may improve morbidity and mortality of AFD 
patients [13].
Our aim was therefore to assess BP levels and analyse 
its clinical implications, compare routine BP measurement 
techniques and describe risk factors for hypertension. Addi-
tionally, we analysed possible correlations between high BP 
and patient’s genotype.
2  Methods
Patients aged 18 years or older with a prior confirmed 
genetic diagnosis of AFD were eligible for inclusion. 
Between January 2015 and May 2019, thirty-two patients 
referred to the Fabry Disease Unit, Nephrology Division 
of San Gerardo Hospital (Monza, Italy) were prospectively 
enrolled in the study. They were twenty-four (75%) females 
and eight (25%) males; all of them gave informed consent.
The included patients (n = 32) accounted for 80% of the 
total eligible Fabry patient cohort (n = 40) at our institu-
tion in that time-period. Accordingly, the following patients 
(20%, n = 8) were excluded from the study: four patients 
refused or failed to perform the 24-h ambulatory blood pres-
sure monitoring (ABPM) and four subjects reported insuf-
ficient clinical or echocardiographic information.
2.1  Blood Pressure Measurements
BP values were obtained by ABPM (oscillometric method), 
office measurements and home recordings. First, during our 
examination, we measured patient’s sitting BP following 
5 min rest and standing BP within 3 min of assuming the 
upright position. Our observed office measurements were 
paired, within 6 months, to ABPM and home blood pres-
sure monitoring results. Patients were invited to monitor 
and record their BP at home for seven consecutive days. 
On each day they took three measurements in the morn-
ing and three in the evening, then the average values were 
logged. Therefore, hypertension was defined according to 
2018 European Society of Cardiology/European Society of 
Hypertension (ESC/ESH) Guidelines for the management of 
arterial hypertension [14] (Supplemental Digital Content 1).
2.2  Characterization of Patients
During the first evaluation, we collected patient’s demo-
graphical characteristics and assessed the occurrence of 
any risk factors related to the development of hypertension.
Information on medications such as enzyme replace-
ment therapy (ERT) or oral chaperone therapy and antihy-
pertensive drugs (calcium channel blockers, ACE inhibitors 
(ACEi), angiotensin II receptor antagonists (ARBs), diuret-
ics and beta-blockers) were also recorded.
Patient genotype and phenotype were characterized. In 
particular, we analysed the different mutations carried by 
each patient (classic, late-onset) and investigated whether 
there could be a statistical correlation between them and the 
occurrence of high BP. Fabry organ damage was analysed 
and in particular we focused on renal and cardiac altera-
tions, which are related with the development of hyperten-
sion [7–11].
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The glomerular filtration rate (GFR) was measured along 
with the albumin-to-creatinine ratio (ACR) and the proteinu-
ria levels on a 24-hours urine collection sample. Accord-
ing to the Kidney Disease Improving Global Outcomes 
(KDIGO) guidelines, chronic kidney disease was classified 
in different levels ranging from G1 to G5 on the GFR scale 
and A1 to A3 on the ACR range [15] (Supplemental Digi-
tal Content 2). Serum electrolyte test and automatic urinary 
sediment analyses were also performed by our routine bio-
chemistry laboratory.
2.2.1  Echocardiographic Examination
During the first examination of our study, parasternal and 
apical 2-dimensional echocardiograms (2D) were acquired 
according to the American Society of Echocardiography/
European Association of Echocardiography (ASE/EAE) 
recommendations [16]. All echocardiograms were per-
formed and analysed by the same experienced cardiolo-
gist. The inter-ventricular septum thickness at end diastole 
(IVSd), the posterior wall thickness at end diastole (PWd) 
and the diameter of the left ventricle at end diastole (LVDd) 
were measured at end-diastole. Left ventricular mass index 
(LVMi) and relative wall thickness (RWT) were calculated 
using the adequate equations [17, 18]. The reference ranges 
for these values were: RWT ≤ 0.42 in males and females, 
LVMi < 115 g/m2 in males and < 95 g/m2 in females. The 
geometric changes of the left ventricle were classified, using 
the LVMi and RWT values, in concentric hypertrophy (ele-
vated RWT with increased LVMi), concentric remodelling 
(elevated RWT with normal LVMi), eccentric hypertrophy 
(normal RWT with increased LVMi) and normal geometry 
(normal RWT with normal LVMi). Data on the ejection frac-
tion (EF), left atrial volume index (LAVi), tricuspid annular 
plane systolic excursion (TAPSE), E/e′ and E/A ratio were 
reported.
2.2.2  Fabry Stabilization Index Assessment
The severity and the stability of the organ involvement were 
assessed through the Fabry Stabilization Index (FASTEX) 
[19]. We calculated the “raw score” based on seven clini-
cal parameters: pain, cerebrovascular events, proteinuria, 
glomerular filtration rate, echocardiography parameters, 
electrocardiographic parameters and New York Heart 
Association (NYHA) class. Two “raw scores” were com-
pared in two consecutive visits one year apart, obtaining the 
FASTEX index: a percentage threshold value that indicates 
if the patient has worsened between one visit and another. 
When FASTEX is equal to or greater than 20%, the patient 
is defined not stable, if less than 20% the patient is in stable 
conditions [19]. The score was obtained using the online 
FASTEX index tool [20].
2.3  Statistical Analysis
Data are given as means ± standard deviation (SD). Statisti-
cal analysis was performed using Microsoft Excel and SPSS 
version 25.0. Mean values were compared by Student’s t-test 
for independent samples and categorical data were analysed 
by the Fisher’s exact test when appropriate.
3  Results
3.1  Blood Pressure Measurements
Out of the whole population (n = 32), the standard office 
and home measurements showed high BP in three (9.37%) 
patients. The ABPM, confirming the previous results, 
allowed us to diagnose hypertension in other three (9.37%) 
cases, for a total of six (18.75%) hypertensive patients. The 
rest of the population (81.25%, n = 26) was normotensive, 
but included four patients with a prior diagnosis of hyper-
tension and currently under an adequate anti-hypertensive 
therapy.
The ABPM of the hypertensive patients showed a mean 
SBP of 138.17 ± 4.88 mmHg and a mean DBP of 81.17 ± 
3.66 mmHg, half (50%, n = 3) of them presented a non-
dipper pattern. One half (50%, n = 3) reported normal office 
BP measurements (SBP 130 ± 2.6 mmHg, DBP 82.33 ± 2.5 
mmHg) and normal home values (SBP 121 ± 8.9 mmHg, 
DBP 82.33 ± 2.1 mmHg). Three patients (50%) presented 
an elevation of both home and office BP levels. In detail, 
the results of the home monitoring revealed a mean SBP of 
133.33 ± 14.77 mmHg and a mean DBP of 89.17 ± 7.63 
mmHg, while the office measurements presented a mean 
SBP of 144.17 ± 16.07 mmHg and a DBP of 90.83 ± 9.91 
mmHg, without differences between sitting and standing 
(Table 1).
The true normotensive patients (68.75%, n = 22) at the 
ABPM revealed a mean SBP of 111.64 ± 10.61 mmHg and 
a mean DBP of 65.68 ± 6.30 mmHg. The office monitor-
ing showed a SBP of 119.09 ± 11.48 mmHg and a DBP of 
73.64 ± 8.47 mmHg while the home measurements a SBP 
of 114.32 ± 10.20 mmHg and a DBP of 65.91 ± 6.40 mmHg 
(Table 1). Only one (3.8%) patient presented elevated BP 
values at the office monitoring, probably due to the “white 
coat syndrome”.
The four patients with a previously known diagnosis of 
hypertension presented a pressure profile (ABPM, home and 
outpatient monitoring) well controlled by the current anti-
hypertensive therapy. At the ABPM showed a normal mean 
SBP of 116.75 ± 1.26 mmHg and a mean DBP of 72.5 ± 
3.70 mmHg along with normal office and home BP monitor-
ing (Table 1).
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3.2  Characterization of the Patients
All patients (n = 32) were Caucasian with an average age of 
50.3 ± 12.4 (22 ÷ 69) years.
They had mostly a sedentary lifestyle (56.25%, n = 18) 
and less than a half of them was affected by dyslipidaemia 
(43.75%, n = 14). Obesity was a rare condition (9.37%, n 
= 3) and the average body mass index was within normal 
ranges (BMI=23.3 ± 4.1). Glucose intolerance and diabetes 
type 2 were uncommon (3.12%, n = 1) and only few of them 
were smokers (21.87%, n = 7) or alcohol consumers (9.37%, 
n = 3) (Table 2).
The six hypertensive patients were all females with an 
average age of 58 ± 10.9 (43÷69) years old, but they were 
not significantly older (p > 0.05) compared with the nor-
motensive patients which had an average age of 48.4 ± 12.4 
(22÷69) years.
They had mostly a sedentary life-style (83.3%, n = 5), 
half of them (50%, n = 3) had a known diagnosis of dys-
lipidaemia and one was considered obese with a BMI > 30. 
Smoking habit and alcohol consumption were a rare condi-
tion (16.6%, n = 1).
Similarly, almost half of the normotensive patients had 
a sedentary life-style and a known diagnosis of dyslipidae-
mia. Two were considered obese. Smoking habit and alcohol 
consumption were a rare condition. The same applies for 
patients with treated hypertension who were also predomi-
nantly sedentary and with a low prevalence of smokers and 
alcohol users (Table 2).
This group of patients were under anti-hypertensive drugs 
such as calcium channel blockers (25%, n = 1) or ACEi 
(50%, n = 2) in combination with beta-blockers (50%, n 
= 2) or diuretics (25%, n = 1). Equally, seven (31.81%) 
of the normotensive patients were taking anti-proteinuric 
drugs (ACEi and ARBs), but all of them had normal BP 
levels (office and home monitoring) even before starting 
the therapy. The remaining (65.6%, n = 21) did not have a 
known diagnosis of hypertension and were not taking any 
anti-hypertensive drug (Table 2).
The 59.4% (n = 19, 12 females and 7 males) of the total 
population was under specific treatment for AFD, two 
(10.52%) were taking migalastat and the majority (89.48%, n 
= 17) were on enzyme replacement therapy (ERT): 41.2% (n 
= 7) on agalsidase-alpha and 58.8% (n = 10) on agalsidase-
beta (Table 2).
The remaining patients (40.6%, n = 13) were still under 
assessment, whereas three (23.07%) of them had already 
refused the therapy.
The phenotypic expression was varied, with more than a 
half of the patients presenting with multi-organ involvement. 
Signs and symptoms mainly involved the nervous (neuro-
pathic pain and dyshidrosis), cardiac (echocardiographic 
alterations) and renal (proteinuria and renal failure) systems 
(Table 3).
Chronic kidney disease ranged mainly from G1/A1 to 
G2/A1 (81.25%, n = 26) while few patients (18.75%, n = 6) 
presented a more advanced renal failure with chronic kidney 
disease (CKD) stages from G3a to G5 and/or albuminuria 
stages from A2 to A3 (Table 2).
Table 1  Blood pressure monitoring
a p value calculated between normotensive patients and those with untreated hypertension
b p value calculated between normotensive patients and those with treated hypertension. Hypertension defined by ABPM
Type of measure Values (mmHg) Overall (n = 
32) mean (SD)
Normotension (n 
= 22), mean (SD)
Untreated Hyperten-
sion (n = 6), mean 
(SD)
p-valuea Treated hyperten-





Systolic 118.22 (11.78) 114.41 (10.91) 132.00 (7.38) < 0.001 118.5 (4.73) 0.245
Diastolic 72.09 (8.99) 68.82 (7.10) 83.83 (5.71) < 0.001 72.5 (8.54) 0.465
Ambulatory BP (night-
time)
Systolic 106.00 (13.32) 102.64 (12.96) 117.17 (13.3) 0.045 107.75 (4.99) 0.194
Diastolic 63.13 (7.77) 60.14 (4.75) 73.33 (9.00) 0.014 64.25 (7.41) 0.353
Ambulatory BP (24 h) Systolic 117.25 (13.69) 111.64 (10.61) 138.17 (4.88) < 0.001 116.75 (1.26) 0.040
Diastolic 69.44 (8.26) 65.68 (6.30) 81.17 (3.66) < 0.001 72.50 (3.70) 0.021
Home BP Systolic 118.91 (13.12) 114.32 (10.20) 133.33 (14.77) 0.023 122.50 (9.95) 0.202
Diastolic 70.94 (11.06) 65.91 (6.40) 89.17 (7.63) < 0.001 71.25 (5.56) 0.151
Office BP Systolic 124.38 (15.20) 119.09 (11.48) 144.17 (16.07) 0.010 123.75 (6.85) 0.307
Diastolic 76.72 (10.92) 73.64 (8.47) 90.83 (9.91) 0.006 72.5 (8.66) 0.820
Office BP (sitting) Systolic 127.72 (14.60) 122.59 (10.95) 147.50 (14.05) 0.003 126.25 (7.50) 0.220
Diastolic 77.47 (10.86) 73.86 (8.29) 91.50 (9.73) 0.002 73.75 (10.31) 0.492
Office BP (standing Systolic 121.03 (16.47) 115.59 (13.10) 140.83 (18.23) 0.009 121.25 (6.99) 0.122
Diastolic 75.97 (11.17) 73.41 (8.90) 90.17 (10.19) 0.004 71.25 (7.50) 0.315
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Three untreated hypertensive patients (50%) presented 
with renal impairment, two with CKD stage G3a/A2 and 
the patient with BMI > 30 showed hyperfiltration (eGFR > 
150 ml/min) (Table 3). They presented a lower (p < 0.05) 
eGFR compared with the normotensive patients, whilst other 
renal indexes were not significantly different between the 
groups (Table 4). No electrolytic imbalance or urinary sedi-
ment alterations were detected. All the hypertensive patients 
had cardiological involvement and peripheral neurological 
manifestations with acroparesthesias and/or hypohidrosis. 
Three patients (50%) presented with gastrointestinal symp-
toms, two out of three experiencing recurrent episodes of 
abdominal pain and one complaining of frequent nausea and 
diarreha. No one had pulmonary or cutaneous involvement. 
Nearly all patients with treated hypertension had cardio-
logical (75%, n = 3) involvement as well as normotensives 
(86.4%, n = 19) (Table 3).
All patients were carriers of heterogeneous GLA gene 
mutations. The majority (71.87%, n = 23) expressed a classic 
or likely-classic [21] mutation. Seven (21,87%) had a late-
onset one, with the most common being the p.Asn215Ser 
(85.71%, n = 6) which has been reported to be associated 
with a late-onset cardiac variant [22]. Two (6.25%) patients 
had a mutation not previously described in literature. In the 
normotensive group sixteen (72.7%) patients had a classic 
or “likely classic” mutation, five a late-onset and one a not-
previously-described one (Table 5). The patients with treated 
hypertension mostly expressed a classical phenotype (75%, 
n = 3) (Table 5) with mainly cardiac involvement (75%, n 
= 3) (Table 3).
Finally, in the hypertensive group, four patients (66.7%) 
were carrying a classic or likely-classic mutation, one a late-
onset and another a not previously described (ND) muta-
tion (Table 5). The correlation test between the prevalence 
Table 2  Characteristics of the patients
Hypertension defined by ABPM
Characteristics Overall (n = 32) Normotension (n = 22) Untreated hyperten-




Sex: female, n (%) 24 (75) 16 (72.7) 6 (100) 2 (50)
Race: Caucasian, n (%) 32 (100) 22 (100) 6 (100) 4 (100)
Age (years), mean (SD) 50.3 (12.4) 48.4 (12.4) 57.8 (10.9) 49.3 (12.6)
Therapy, n (%)
 Anti-proteinuric therapy 7 (21.9) 7 (31.8) 0 (0) 0 (0)
  ACE-inhibitors 5 (71.4) 5 (71.4) 0 (0) 0 (0)
  Angiotensin II receptor antagonists 2 (28.6) 2 (28.6) 0 (0) 0 (0)
 Anti-hypertensive therapy 4 (12.5)§ 0 (0) 0 (0) 4 (100)§
  Beta-blockers 2 (50) 0 (0) 0 (0) 2 (50)
  Diuretics 1 (25) 0 (0) 0 (0) 1 (25)
  ACE-inhibitors 2 (50) 0 (0) 0 (0) 2 (50)
  Calcium channel blockers 1 (25) 0 (0) 0 (0) 1 (25)
 Enzyme replacement therapy 17 (53.1) 12 (54.5) 3 (50) 2 (50)
  Agalsidase-alpha 7 (41.2) 5 (41.7) 1 (33.3) 1 (50)
  Agalsidase-beta 10 (58.8) 7 (58.3) 2 (66.7) 1 (50)
 Chaperone therapy 2 (6.3) 0 (0) 1 (16.7) 1 (25)
Risk factors for hypertension, n (%)
 Dyslipidaemia 14 (43.8) 10 (45.5) 3 (50) 1 (25)
 Sedentary life-style 18 (56.3) 10 (45.5) 5 (83.3) 3 (75)
 Obesity 3 (9.4) 2 (9.1) 1 (16.7) 0 (0)
  BMI (kg/m2), mean (SD) 23.3 (4.1) 23.4 (4.2) 22.8 (4.6) 23.9 (3.2)
 Smoke 7 (21.9) 5 (22.7) 1 (16.7) 1 (25)
 Alcohol consumption 3 (9.4) 2 (9.1) 1 (16.7) 0 (0)
 Positive family history 12 (37.5) 8 (36.4) 2 (33.3) 2 (50)
 Glucose intolerance 1 (3.1) 0 (0) 1 (16.7) 0 (0)
 CKD stage G1–G2/A1 26 (81.25) 19 (86.4) 4 (66.7) 3 (75)
 CKD stage G3a–G5/A2–A3 6 (18.75) 3 (13.6) 2 (33.3) 1 (25)
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hypertension and the type of mutations, classical or late-
onset, was not significant (p > 0.05).
3.2.1  Echocardiographic Examination
The echocardiogram examination showed an all-over high 
prevalence of cardiac hypertrophy; thirteen (40.6%) patients 
presented a concentric hypertrophy, seven (21.9%) a concen-
tric remodelling and twelve (37.5%) had normal parameters. 
All the untreated hypertensive patients (18.75%, n = 6) were 
diagnosed with concentric hypertrophy with a significantly 
higher LVPWD (p < 0.05) and LVMi (p < 0.05) compared to 
the normotensive patients. All the other echocardiographic 
Table 3  Fabry organ 
involvement
Hypertension defined by ABPM







n = 32 n = 22 n = 6 n = 4
Nervous system 21 (65.6) 14 (63.6) 6 (100) 1 (25)
Neuropathic pain 15 (71.4) 9 (64.3) 5 (83.3) 1 (100)
Dyshidrosis 9 (42.9) 7 (50) 2 (33.3) 0 (0)
White matter lesions 3 (14.3) 3 (21.4) 0 (0) 0 (0)
Neurological events 1 (4.8) 1 (7.1) 0 (0) 0 (0)
Renal system 10 (32.3) 6 (27.3) 3 (50) 1 (25)
ACR > 30 mg/g 6 (60) 3 (50) 2 (66.7) 1 (100)
GFR < 60 ml/min 3 (30) 1 (16.7) 2 (66.7) 0 (0)
GFR > 150 ml/min 4 (40) 3 (50) 1 (33.3) 0 (0)
Cardiac system 29 (90.6) 19 (86.4) 6 (100) 4 (100)
Echo alterations (LVH) 20 (68.9) 11 (57.9) 6 (100) 3 (75)
Cardiac events 0 (0) 0 (0) 0 (0) 0 (0)
Gastrointestinal system 12 (37.5) 8 (36.4) 3 (50) 1 (25)
Abdominal pain 10 (83.3) 7 (87.5) 2 (66.7) 1 (100)
Nausea 2 (16.7) 1 (12.5) 1 (33.3) 0 (0)
Diarreha 3 (25) 2 (25) 1 (33.3) 0 (0)
Cutaneous system 4 (12.5) 4 (18.2) 0 (0) 0 (0)
Angiokeratomas 4 (100) 4 (100) 0 (0) 0 (0)
Respiratory system 7 (21.9) 7 (31.9) 0 (0) 0 (0)
Shortness of breath 7 (100) 7 (100) 0 (0) 0 (0)
Respiratory failure 0 (0) 0 (0) 0 (0) 0 (0)
Sensory system 22 (68.8) 15 (68.2) 5 (83.3) 2 (50)
Cornea verticillata 15 (68.2) 9 (60) 4 (80) 2 (100)
Hearing impairment 7 (31.8) 5 (33.3) 1 (20) 1 (50)
Vertigo 4 (18.2) 4 (26.7) 0 (0) 0 (0)
Table 4  Renal function assessment
a p value calculated between normotensive patients and those with untreated hypertension
b p value calculated between normotensive patients and those with treated hypertension. Hypertension defined by ABPM
Characteristics Overall (n = 32) Normotension (n = 22) Untreated hyper-
tension (n = 6)
p-valuea Treated hyper-
tension (n = 4)
p-valueb
Renal function, means (SD)
Serum creatinine (mg/dl) 0.88 (0.2) 0.85 (0.2) 0.97 (0.2) 0.09 0.90 (0.1) 0.29
eGFR (ml/min/1.73m2) 95.6 (35.5) 104.15 (34.3) 70.4 (40.8) 0.04 86.4 (10.2) 0.03
Proteinuria (mg/24h) 135.3 (102.9) 136.73 (90.8) 121.3 (41.7) 0.28 148.5 (219.2) 0.46
ACR (mg/g) 39.4 (60.6) 36.0 (67.8) 50.8 (44.0) 0.27 40.6 (46.1) 0.44
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parameters were not significantly different between hyper-
tensive and normotensive patients.
All the treated hypertensive patients (12.5%, n = 4) pre-
sented a concentric hypertrophy, but no statistically sig-
nificant differences were found between this group and the 
normotensive one (Table 6).
3.2.2  FASTEX Assessment
In the overall study population (n = 32), eight (25%) 
patients presented a progressive form of AFD accord-
ingly to the FASTEX score. Four out of the six (66.7%) 
hypertensive subjects were classified as progressive, 
while a great portion (86.4%, n = 19) of the normotensive 
group was not. The majority (75%, n = 3) of well treated 
hypertensive patients also showed a stable FASTEX score 
(Figure 1).
4  Discussion
In this study, the majority of AFD patients (68.75%, n 
= 22) were normotensive without specific blood pres-
sure control therapy. Four (12.5%) patients previously 
Table 5  Analysis of Fabry mutations [23]









1 65 F c.515G>A p.Cys172Tyr Missense Classic Yes No No
2 61 F c.155G>A p.Cys52Tyr Missense Classic Yes No Treated
3 57 F c.155G>A p.Cys52Tyr Missense Classic Yes Yes No
4 51 F c.824T>A p.Leu275His Missense Classic Yes Yes No
5 56 F c.708G>C p.Trp236Cys Missense Classic Yes No No
6 32 F c.658C>T p.Arg220Ter Nonsense Classic Yes No No
7 63 F c.658C>T p.Arg220Ter Nonsense Classic Yes Yes Yes
8 22 M c.901C>T p.Arg301Ter Nonsense Classic Yes Yes No
9 45 F c.901C>T p.Arg301Ter Nonsense Classic Yes No No
10 39 F c.4C>T p.Gln2Ter Nonsense Classic Yes Yes No
11 59 M c.4C>T p.Gln2Ter Nonsense Classic Yes No No
12 27 M c.4C>T p.Gln2Ter Nonsense Classic Yes Yes No
13 39 M c.1024C>T p.R342X Nonsense Classic No No No
14 63 F c.233C>G p.Ser78Ter Nonsense Classic No No No
15 60 M c.644A>G p.Asn215Ser Missense Later Onset Yes No No
16 46 F c.644A>G p.Asn215Ser Missense Later Onset Yes No No
17 56 F c.644A>G p.Asn215Ser Missense Later Onset Yes No No
18 61 F c.644A>G p.Asn215Ser Missense Later Onset No No No
19 34 M c.644A>G p.Asn215Ser Missense Later Onset Yes No Treated
20 49 F c.644A>G p.Asn215Ser Missense Later Onset Yes Yes Yes
21 39 F c.272T>C p.Ile91Thr Missense Later Onset Yes No No
22 49 M c.370-2A>G p.Y123C Consensus splice Likely Classic Yes Yes No
23 69 F c.428dupC p.G144Qfs*12 Frameshift Likely Classic Yes Yes Yes
24 57 F c.806G>U p.G261C Missense Likely Classic Yes No No
25 58 M c.806G>U p.G261C Missense Likely Classic Yes Yes Treated
26 54 F c.806G>U p.G261C Missense Likely Classic Yes Yes Yes
27 44 F c.824T>A p.Leu275His Missense Likely Classic Yes No Treated


















30 63 F c.124-125delAT p.Met42GlyfsTer13 Deletion Classic Yes No No
31 43 F c.634-
639delAAAAG 
p.Q212fsX230 ND ND Yes No Yes
32 39 F c.73delGfsX120 p.Asp25Thrfs96x ND ND Yes No No
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diagnosed with hypertension and currently under anti-
hypertensive treatment showed a well-controlled blood 
pressure, while six (18.75%) were diagnosed with uncon-
trolled hypertension for the first time, due to the ABPM 
measurements. Half of them presented a non-dipping 
blood pressure pattern, which is shown to be associated 
with additional cardiovascular alterations and organ dam-
age [24]. Of note, half of these patients had normal blood 
pressure recordings in office and home measurements; 
masked hypertension was diagnosed with 24-h blood pres-
sure measurements highlighting the need of standardized 
long-term recordings, especially in patients with concomi-
tant early signs of cardiomyopathy and/or nephropathy.
Our findings in the AFD population are in line with a 
recent presentation that shows that masked hypertension 
may have an average prevalence of about 40% in CKD-
patients [25].
Apart from dyslipidaemia and sedentary lifestyle, the 
overall population revealed a low prevalence of well-known 
risk factors for the development of hypertension such 
obesity, glucose intolerance and diabetes, smoke habit and 
alcohol consumption.
The hypertensive group showed a higher prevalence 
of kidney involvement with the development of proteinu-
ria and renal failure, supporting previous reports [7–11]. 
Almost all of them presented electrocardiographic and 
echocardiographic alterations and the echocardiographic 
analysis highlighted that patients with uncontrolled hyper-
tension showed a worse cardiac hypertrophy as compared 
to the well treated-hypertensive patients.
The majority of the hypertensive patients presented 
a progressive disease through the FASTEX, indexes of 
progressive renal damage are included in determining the 
score and renal failure and its progression can be consid-
ered a crucial factor in the development of hypertension 
Moreover, untreated high blood pressure values represent 
an established risk factor for adverse cardiovascular and 
kidney outcomes [25, 26].
In addition, hypertensive AFD patients showed a higher 
prevalence of classical mutations, related to a more severe 
phenotype compared with the late-onset ones, mainly 
involving one organ system such as the neuro-vegetative, 
cardiological or renal one [27].
In our study, the prevalence of hypertensive patients 
was lower as compared to several previous published 
papers [7–10]. For instance, our results are in contrast 
to the report by Kleinert et al. [7] which showed a high 
overall rate of uncontrolled hypertension (57% in male 
patients) in a population of 391 patients affected by AFD. 
We described a lower prevalence of hypertension despite 
the average age of our patients being higher. Furthermore, 
the majority of our patients were female, and none of our 
patients had severe kidney failure, ESRD, needed dialysis 
or had received a kidney transplantation. In addition, the 
criteria for the diagnosis of hypertension differs slightly 
Table 6  Echocardiographic data
a p value calculated between normotensive patients and those with untreated hypertension
b p value calculated between normotensive patients and those with treated hypertension. Hypertension defined by ABPM
Overall (n = 32), 
mean (SD)
Normotension (n = 
22), mean (SD)
Untreated hypertension (n 
= 6), mean (SD)
p-valuea Treated hypertension (n 
= 4), mean (SD)
p-valueb
LVDd (cm) 4.35 (0.38) 4.35 (0.43) 4.35 (0.20) 0.485 4.35 (0.26) 0.489
PWd (cm) 1.04 (0.20) 0.99 (0.18) 1.18 (0.22) 0.044 1.11 (0.14) 0.101
IVSd (cm) 1.13 (0.26) 1.05 (0.22) 1.32 (0.33) 0.055 1.28 (0.22) 0.066
 RWT 0.48 (0.10) 0.46 (0.10) 0.55 (0.11) 0.118 0.51 (0.09) 0.346
LVMi (g/m2) 97.44 (29.03) 90.37 (28.13) 115.82 (25.26) 0.033 108.75 (29.88) 0.162
 EF (%) 67.63 (4.92) 67.86 (4.36) 66.67 (5.57) 0.321 67.75 (7.93) 0.490
  E/e′ 9.48 (2.63) 9.13 (3.07) 10.34 (0.98) 0.063 10.10 (0.96) 0.124
LAVi (ml/m2) 33.66 (17.20) 30.77 (6.96) 45.67 (37.51) 0.188 31.50 (4.20) 0.393
TAPSE (cm) 2.28 (0.34) 2.33 (0.25) 2.15 (0.51) 0.221 2.25 (0.51) 0.392










0% 20% 40% 60% 80% 100%
Stable Not stable
Fig. 1  Fabry Stabilization Index (FASTEX) score
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between the two studies. It is significant to point out that 
we analysed a smaller sample size, but our blood pressure 
monitoring was strictly structured.
Notably, our hypertensive patients were identified by 
automated and home blood pressure analyses, highlight-
ing the need of well standardized blood pressure measuring 
routines in the follow-up of Fabry patients as half of them 
presented with normal office blood pressure. An important 
observation in our study is the association between non-
controlled hypertension and clinically progressive disease, 
not seen in those patients where blood pressure was well 
controlled by antihypertensive agents at the time of inclu-
sion. Of note, our observation also highlights the necessity 
of diagnosing the often-overlooked masked hypertension in 
AFD patients with early progressive cardiac or renal disease.
Moreover, a study on 10,051 individuals (53.2% female, 
age 56.2 ± 16.8 years) revealed that the prevalence of 
hypertension in Italy varies from 55 to 59% [28]. Taking 
into account the limitations of a comparison between these 
studies, our data indicate that hypertension is not a frequent 
finding in stable and well-monitored AFD patients, who are 
likely to have a lower prevalence compared to the general 
population with the same age range. This is consistent with 
the general concept that Fabry disease often is accompanied 
by lower blood pressure levels, which in fact may limit the 
anti-proteinuric use of ACEi/RAS-blockade in many patients 
[29]. Our findings may help raise the awareness of masked 
hypertension in Fabry disease patients. The purpose of a 
close blood pressure control in AFD population is impor-
tant to reduce cardiovascular events and progressive dete-
rioration of renal function. We recommend the inclusion of 
ABPM for a reliable monitoring of BP in routine follow-up 
of AFD patients. Other studies in CKD patients confirm that 
the routine office BP measurements provide imprecise reflec-
tion of the actual BP load [25, 30] as recommended by the 
ESC-ESH Guidelines 2018 [31].
The mechanisms connecting Fabry disease to the devel-
opment of hypertension have not been fully studied yet. 
Hypertension might be a consequence of an AFD associ-
ated vascular disease.
It is not known whether the vascular disease originates 
from the deposition of glycosphingolipids in endothelial 
cells or in smooth muscle cells in the arterial media layer 
[32, 33]. Growing evidence indicates that the deposition of 
Gb3 in the endothelium activates oxidative enzymes such 
as nicotinamide adenine dinucleotide phosphate (NADPH) 
oxidases leading to the production of reactive oxygen spe-
cies (ROS) [34]. Moreover, storage of glycosphingolipids 
in smooth muscle cells may promote cell proliferation with 
fibrotic remodelling of the arterial wall leading to arterial 
wall stiffness resulting in shear stress that may increase the 
expression of angiotensin 1 and 2 receptors in endothelial 
cells, increasing ROS, NF-kB, beta-integrin and cyclooxy-
genase 1 and 2 activity and decreasing nitric oxide synthesis 
[35]. These mechanisms may lead to oxidative stress and 
inflammatory damage which promotes endothelial and vas-
cular dysfunction leading to the development of hyperten-
sion [36].
Patients affected by Fabry disease may also develop 
hypertension due to a direct renal damage [8] caused by 
the accumulation of glycolipids within the tubular epithelial 
cells and the podocytes, leading to tubular atrophy, intersti-
tial fibrosis and segmental and global glomerulosclerosis 
[37].
It has long been accepted the concept that renal impair-
ment and hypertension are closely associated [38]. Sustained 
and untreated high blood pressure values hasten the progres-
sion of kidney disease and, in turn, renal damage is clearly 
related to the development of hypertension [39].
Another theory speculates that hypertension may be a 
process unrelated to Fabry disease, such as in the case of 
essential hypertension [12]. Additionally, kidney biopsy 
reports have shown concomitant renal diseases causing 
hypertension that may co-exist with Fabry disease (e.g., 
focal and segmental glomerular sclerosis, membranous or 
IgA nephropathy) [40–43].
However, we can speculate that glycolipids accumulation 
may also affect the autonomic nervous system causing an 
impairment of the arterial baroreflex function [44], lead-
ing to an altered blood pressure regulation, with possible 
orthostatic hypotension and predisposition to syncope [9] 
even if we did not diagnose any orthostatic hypotension in 
our patients.
The limitations of our study are the small sample size of 
the population analysed and the higher prevalence of women 
compared to men. It is important to underline also the lack 
in the analysis of the patients eating habits, the sodium 
intake and natriuresis. Enlisting a control group of non-AFD 
patients would have helped to better develop the analysis. 
Data on prolonged follow-up are not available, therefore the 
prognostic impact of hypertension and its consequences can-
not be clearly reported.
The strength of the study are the accurate characterization 
of the patients and the meticulous BP monitoring according 
to current guidelines.
5  Conclusions
The results of our study underline that hypertension can be 
found in a restricted portion of stable and well-monitored 
AFD patients with minimal signs of organ complications, 
becoming more prevalent in clinically progressive cases. The 
ABPM proved to be useful to reveal the cases of masked 
318 F. Rossi et al.
hypertension which, if not properly diagnosed, can con-
tribute to the progressive worsening of the organ damage. 
We recommend a standardised ambulatory long-term blood 
pressure monitoring program and timely antihypertensive 
intervention to improve the outcome of AFD patients.
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